Form 4: Foghorn Therapeutics Director Acquires Stock Options

Director Neil Gallagher acquired 50,000 stock options in Foghorn Therapeutics Inc. on May 1, 2025.

Summary

• On May 1, 2025, Neil Gallagher, a director of Foghorn Therapeutics Inc., acquired 50,000 stock options.
• The exercise price of these options is $4.16.
• The options vest in three equal annual installments, contingent upon continued service on the board of directors.
• The options expire on April 30, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director suggests confidence in the company, but it's a routine transaction.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock option grants to directors are a common practice in the biotechnology industry to align their interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one-third annually over three years is also a typical arrangement.
• Comparable companies like BioNTech or Moderna also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates

Keywords

stock options, Foghorn Therapeutics, director, acquisition, FHTX, Neil Gallagher, Form 4